Regeneron Pharmaceuticals Gestione
Criteri Gestione verificati 4/4
Regeneron Pharmaceuticals Il CEO è Leonard Schleifer, nominato in Jan1988, e ha un mandato di 38.5 anni. la retribuzione annua totale è $ 7.28M, composta da 27.2% di stipendio e 72.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.37% delle azioni della società, per un valore di $ 1.75B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.5 anni e 19.6 anni.
Informazioni chiave
Leonard Schleifer
Amministratore delegato
US$7.3m
Compenso totale
| Percentuale dello stipendio del CEO | 27.19% |
| Mandato del CEO | 38.5yrs |
| Proprietà del CEO | 2.4% |
| Durata media del management | 5.5yrs |
| Durata media del Consiglio di amministrazione | 19.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Seeking Alpha • Jul 25
Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins
Summary Regeneron Pharmaceuticals, Inc. remains a Buy, supported by robust revenue drivers Dupixent and Libtayo, despite recent share price volatility and underperformance versus the S&P. Dupixent’s expanding indications and sustained growth, along with Libtayo’s oncology momentum, underpin forward revenue expectations, even as Eylea faces biosimilar headwinds. Recent margin and ROIC declines are primarily due to accelerated Sanofi repayments and deferred tax asset accumulation, both expected to reverse, improving profitability from Q3 2026. REGN has a strong balance sheet, prudent capital allocation, and a deep pipeline that position REGN for a new growth phase, with operating margins and ROIC likely bottoming in 2026. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jun 24
REGN: Core Immunology Cash Flows Will Support Pipeline And Oncology Upside
Regeneron Pharmaceuticals' updated analyst fair value has shifted lower by about $42 to $833, as analysts factor in reduced expectations for the fianlimab program after recent Phase 3 trial disappointments, softer modeled revenue growth and margins, and a lower assumed future P/E multiple. Analyst Commentary Recent research on Regeneron Pharmaceuticals centers on the impact of fianlimab trial results, competitive pressures around key franchises, and how these factors feed into earnings forecasts and valuation multiples.
Aggiornamento narrativa • Jun 09
REGN: Future Re Rating Will Hinge On Reset Oncology Pipeline Optionality
Analysts have reduced their fair value estimate for Regeneron Pharmaceuticals to $1,000 from $1,030 after a series of lower Street price targets followed the company’s disappointing Phase 3 fianlimab and LAG-3 melanoma trial results. Analyst Commentary Street research following the fianlimab and LAG-3 melanoma trial update has been active, with most recent moves skewed toward lower fair value assumptions and, in some cases, rating downgrades.
Aggiornamento narrativa • May 26
REGN: Fair Outlook As LAG 3 Setback Reshapes Pipeline And Product Prospects
Analysts have trimmed their fair value estimate for Regeneron Pharmaceuticals to $641 from $730, reflecting lower assumed profit margins and a reduced future P/E multiple after the recent fianlimab LAG-3 trial setbacks and related cuts to price targets across the Street. Analyst Commentary Street research has turned more cautious on Regeneron following the failed Phase 3 LAG-3 melanoma trial for fianlimab, with a series of reduced price targets and several rating downgrades.Aggiornamento narrativa • May 03
REGN: Expanding Immunology And Gene Therapy Will Support Future Upside
Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street. Analyst Commentary Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months.Aggiornamento narrativa • Apr 19
REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects
Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.Aggiornamento narrativa • Apr 04
REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline
Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.Aggiornamento narrativa • Mar 21
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.Aggiornamento narrativa • Mar 07
REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.Aggiornamento narrativa • Feb 21
REGN: Fair Outlook As Future Pipeline And Spending Risks Remain
Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.Aggiornamento narrativa • Feb 06
REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating
Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.Aggiornamento narrativa • Jan 23
REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.Aggiornamento narrativa • Jan 09
REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks
Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.Aggiornamento narrativa • Dec 25
REGN: Future Pipeline And Spending Risks Likely To Pressure Shares
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.Aggiornamento narrativa • Dec 11
REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.Aggiornamento narrativa • Nov 27
REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks
Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.Articolo di analisi • Nov 19
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...Aggiornamento narrativa • Nov 12
REGN: Positive Trial Results And Approval Will Drive Continued Momentum
Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.Articolo di analisi • Nov 09
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...Aggiornamento narrativa • Oct 28
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.Aggiornamento narrativa • Sep 18
Broad Pipeline And Global Access Will Build Future Success
Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$4b |
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$7m | US$2m | US$5b |
| Sep 30 2025 | n/a | n/a | US$5b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$7m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$4b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$8m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$4b |
| Mar 31 2023 | n/a | n/a | US$4b |
| Dec 31 2022 | US$7m | US$2m | US$4b |
| Sep 30 2022 | n/a | n/a | US$5b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$6m | US$2m | US$8b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$135m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$21m | US$1m | US$2b |
Compensazione vs Mercato: La retribuzione totale di Leonard ($USD 7.28M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 14.63M ).
Compensazione vs guadagni: La retribuzione di Leonard è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Leonard Schleifer (73 yo)
38.5yrs
Mandato
US$7,280,549
Compensazione
Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 38.5yrs | US$7.28m | 2.37% $ 1.7b | |
| Co-Founder | 25.5yrs | US$6.95m | 1.15% $ 846.9m | |
| Executive VP of Finance & CFO | 2.4yrs | US$6.99m | 0.021% $ 15.8m | |
| Executive VP | 14.8yrs | US$7.46m | 0.042% $ 30.7m | |
| Executive VP of Research & Co-Chief Scientific Officer | 7.5yrs | US$8.48m | 0.051% $ 37.8m | |
| Executive VP and GM of Industrial Operations & Product Supply | 18.3yrs | US$8.78m | 0.035% $ 25.5m | |
| Senior Vice President of Quality Assurance & Operations | 1.5yrs | Nessun dato | Nessun dato | |
| Executive VP | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Investor Relations & Strategic Analysis | no data | Nessun dato | Nessun dato | |
| Senior VP & Chief Compliance Officer | 3.5yrs | Nessun dato | Nessun dato | |
| Senior VP of Human Resources & Chief Human Resources Officer | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Public Policy & Government Affairs | 5.5yrs | Nessun dato | Nessun dato |
5.5yrs
Durata media
66.5yo
Età media
Gestione esperta: Il team dirigenziale di REGN è esperto e expertise (durata media dell'incarico 5.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 38.5yrs | US$7.28m | 2.37% $ 1.7b | |
| Co-Founder | 25.5yrs | US$6.95m | 1.15% $ 846.9m | |
| Lead Independent Director | 15.7yrs | US$775.42k | 0.0038% $ 2.8m | |
| Independent Director | 23.5yrs | US$725.42k | 0.015% $ 11.3m | |
| Independent Director | 35.1yrs | US$730.42k | 0.011% $ 8.3m | |
| Independent Director | 35.1yrs | US$715.42k | 0.0052% $ 3.9m | |
| Independent Director | 38.5yrs | US$730.42k | 0.031% $ 23.0m | |
| Independent Director | 9.5yrs | US$717.83k | 0.00033% $ 243.3k | |
| Independent Director | 3.8yrs | US$705.17k | 0% $ 0 | |
| Independent Director | 9.8yrs | US$720.42k | 0% $ 0 | |
| Independent Director | 9.8yrs | US$715.42k | 0.00032% $ 235.9k | |
| Independent Director | 2.8yrs | US$701.54k | 0% $ 0 |
19.6yrs
Durata media
73yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di REGN è composto da personale esperto e esperto (durata media dell'incarico 19.6 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/31 08:50 |
| Prezzo dell'azione a fine giornata | 2026/07/31 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Regeneron Pharmaceuticals, Inc. è coperta da 55 analisti. 25 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Eliana Merle | Barclays |